中药药源性肝损伤的文献评价研究
Literature evaluation study on herb-induced liver injury
霍光远 1付丽红 1高月求1
作者信息
- 1. 上海中医药大学附属曙光医院肝病科,上海 201203
- 折叠
摘要
目的:中药的使用主要分为3种方式:单味药材或饮片、复方汤剂、单味或复方制剂.本研究制定这三类中药相关风险分类表,以指导合理临床用药.方法:研究在7个电子数据库中检索有关中药药源性肝损伤的临床报告,收集文章的基本信息、用药,并进行风险程度分类:第一类药物(单个中心的个案报道);第二类药物(单个中心的多人报道);第三类药物(多中心报道).结果:第一类包括65种单味药材或饮片和145种单味或复方制剂,第二类包括62种单味药材或饮片和120种单味或复方制剂,第三类包括51种单味药材或饮片和92种单味或复方制剂.分类类别越高,循证级别越强,可疑肝毒性就越大.结论:评价其肝毒性风险时应根据其分类区别对待.新发现的肝毒性中药制剂,其相关毒理机制有待进一步探索.
Abstract
Objective:The use of Chinese medicines is categorized into three main methods:Single herbs or tablets,compound decoctions,and single and compound preparations.This study develops a classification table of the risks associated with these three Chinese medicines to guide rational clinical use.Methods:In this study,we searched seven electronic databases for clinical reports on drug-induced liver injury from Chinese medicines,collected basic information about the articles,and medications used,and classified the risk into three categories:class Ⅰ(case reports from a single center),class Ⅱ(multiple reports from a single center),and class Ⅲ(reports from multiple centers).Results:Class Ⅰ comprised 65 single herbs or tablets and 145 of both single and compound preparations,class Ⅱ included 62 single herbs or tablets and 120 of both single and compound preparations,and class Ⅲ consisted of 51 Single herbs or tablets and 92 of both single and compound preparations.The higher the classification,the stronger the level of evidence and the greater the suspected hepatotoxicity.Conclusion:Hepatotoxicity risk should be assessed differently based on their classification.The toxicological mechanisms of newly identified hepatotoxic Chinese medicine preparations await further investigation.
关键词
药物性肝损伤/中药药源性肝损伤/不良反应/循证医学/合理用药Key words
Drug-induced liver injury/Herb-induced liver injury/Adverse effect/Evidence-based medicine/Rational therapy引用本文复制引用
基金项目
上海市临床重点专科建设项目(shslczdzk01201)
上海市2020年度"科技创新行动计划"医学创新研究专项项目(20Z21900100)
上海市进一步加快中医药传承创新发展三年行动计划(2021-2023年)(ZY2021-2023-0103)
上海市进一步加快中医药传承创新发展三年行动计划(2021-2023年)(ZY2021-2023-0302)
上海炎癌转化病证生物学前沿研究基地(2021KJ03-12)
出版年
2024
国家科技期刊平台
NSTL
万方数据